# Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine in HIV-1 Infected Transgender Women

> **NCT03033836** · PHASE4 · COMPLETED · sponsor: **Fundación Huésped** · enrollment: 60 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** ARV treatment

## Key facts

- **NCT ID:** NCT03033836
- **Lead sponsor:** Fundación Huésped
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2019-06-28
- **Final completion:** 2019-06-28
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2019-08-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03033836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03033836, "Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine in HIV-1 Infected Transgender Women". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03033836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*